盐酸米托蒽醌脂质体联合阿糖胞苷治疗伴RUNX1∷MTG16融合基因的儿童急性髓系白血病一例并文献复习
本文报告1例13岁男性儿童急性髓系白血病(AML)伴RUNX1∷MTG16融合基因及FLT3-ITD突变,经盐酸米托蒽醌脂质体联合阿糖胞苷(MA)方案诱导达完全缓解,序贯1个疗程后融合基因及突变转阴,继续巩固强化治疗中转为阳性,后行同胞全相合脐血造血干细胞移植存活。
要点
- 儿童AML伴RUNX1∷MTG16融合基因可合并FLT3-ITD突变。
- MA方案诱导化疗可达完全缓解,序贯MA方案后融合基因及突变转阴。
- 巩固强化治疗中融合基因及突变转为阳性,行同胞全相合脐血移植后存活。
核心结论
- 伴RUNX1∷MTG16融合基因及FLT3-ITD突变的儿童AML经MA方案诱导达完全缓解,序贯MA方案后融合基因及突变转阴,继续巩固强化治疗中转为阳性,行同胞全相合脐血造血干细胞移植存活。
研究设计与样本
- 回顾性分析中国医学科学院血液病医院2023年10月收治的1例AML伴RUNX1∷MTG16患儿,男性,13岁,因乏力20 d就诊。
主要发现
- 骨髓细胞形态学可见17.0%原始细胞,染色体核型46,XY,t(16;21)(q24;q22),RUNX1∷MTG16融合基因阳性,合并FLT3-ITD突变。
- 经盐酸米托蒽醌脂质体联合阿糖胞苷(MA)方案诱导化疗达到完全缓解。
- 序贯MA方案1个疗程后RUNX1∷MTG16融合基因及FLT3-ITD突变均转阴。
- 继续巩固强化治疗中融合基因及突变均转为阳性,行同胞全相合脐血造血干细胞移植存活。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This case report presents a patient with pediatric acute myeloid leukemia (AML) with RUNX1∷MTG16, admitted to the Blood Disease Hospital of the Chinese Academy of Medical Sciences in October 2023. He was 13 years old, with a chief complaint of fatigue for 20 days. Bone marrow smear revealed 17.0% blasts, the karyotype was 46,XY,t (16; 21) (q24; q22), molecular biology demonstrated RUNX1∷MTG16 fusion gene, combined with FLT3-ITD mutation. The child was diagnosed with AML (with RUNX1 ∷ MTG16). Complete remission was achieved after chemotherapy induction. The induction therapy regimen was mitoxantrone hydrochloride liposomes combined with cytarabine (MA). The RUNX1 ∷ MTG16 and FLT3-ITD were negative after another MA treatment course. However, the RUNX1 ∷ MTG16 and FLT3-ITD were turning positive during the following intensive treatment, and he then successfully underwent matched sibling donor umbilical cord blood transplantation. 回顾性分析中国医学科学院血液病医院2023年10月收治的1例急性髓系白血病(AML)伴RUNX1∷MTG16患儿,男性,13岁,因"乏力20 d"就诊,骨髓细胞形态学可见17.0%原始细胞,染色体核型46,XY,t(16;21)(q24;q22),RUNX1∷MTG16融合基因阳性,合并FLT3-ITD突变,诊断为AML(伴RUNX1∷MTG16)。经盐酸米托蒽醌脂质体联合阿糖胞苷(MA)方案诱导化疗达到完全缓解,序贯MA方案1个疗程后RUNX1∷MTG16融合基因及FLT3-ITD突变均转阴。但继续巩固强化治疗中融合基因及突变均转为阳性,行同胞全相合脐血造血干细胞移植存活。.
引用
- Lin S, Qi BQ, Liu LP, et al. [Mitoxantrone hydrochloride liposome combined with cytarabine for treating pediatric acute myeloid leukemia with RUNX1∷MTG16 fusion gene: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39765356. doi:10.3760/cma.j.cn121090-20240805-00289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。